OwlyTimes

#fda

14 articles with this tag

FDA faces leadership crisis as drug approval stability faltersHealth

FDA faces leadership crisis as drug approval stability falters

The White House replaced the FDA commissioner on May 8, 2026, creating uncertainty regarding the clinical vetting process for new medical drug approvals.

NYT Report Says FDA Blocked Covid and Shingles Vaccine Safety StudyScience

NYT Report Says FDA Blocked Covid and Shingles Vaccine Safety Study

The New York Times reports that the FDA blocked the publication of a government research study confirming the safety of Covid and shingles vaccines today.

90% of Psychedelic Retreats Ignore Safe Antidepressant Taper RulesBusiness

90% of Psychedelic Retreats Ignore Safe Antidepressant Taper Rules

A JAMA Network Open study finds 90% of psychedelic retreats push clients to stop antidepressants in one day, ignoring the 12-week taper medical experts advise.

Trump Order Eases Research Barriers for Schedule I CompoundsHealth

Trump Order Eases Research Barriers for Schedule I Compounds

President Donald Trump signed an executive order directing federal agencies to accelerate clinical research on Schedule I compounds for medical treatments.

FDA Tanning Bed Decision: Autonomy, Risk & a Public Health ShiftHealth

FDA Tanning Bed Decision: Autonomy, Risk & a Public Health Shift

Uncover the surprising FDA tanning bed decision! We analyze the complex clash of autonomy vs. risk, revealing a concerning shift in public health policy.

CDC & FDA Trust Erodes: Doctors Now Key Health SignalHealth

CDC & FDA Trust Erodes: Doctors Now Key Health Signal

Uncover why Americans are turning to doctors for health guidance, not the CDC or FDA. Our analysis reveals a critical shift in trust – and what it means.

FDA Loophole: Unknown Chemicals in Your Food – AnalysisHealth

FDA Loophole: Unknown Chemicals in Your Food – Analysis

Uncover a hidden FDA loophole allowing unknown chemicals in your food! Our analysis reveals how companies self-determine safety, shifting risk to you. Lear...

Biosimilar Stalemate: Why Lower Drug Costs Aren't ArrivingHealth

Biosimilar Stalemate: Why Lower Drug Costs Aren't Arriving

Unlocking the biosimilar puzzle: Discover why lower drug costs haven't materialized. Our analysis exposes the hidden forces stalling competition & impactin...

Trump FDA: $3.2B Lobbying Surge Signals Shift in Drug RulesBusiness

Trump FDA: $3.2B Lobbying Surge Signals Shift in Drug Rules

Uncover how a $3.2B lobbying surge is reshaping FDA drug approval. Our analysis reveals a critical shift—and what it means for patient access & costs.

Protein Fortification: FDA Scrutiny Signals a ShiftHealth

Protein Fortification: FDA Scrutiny Signals a Shift

Is the FDA overlooking a protein overload? We analyze the rise of protein fortification, revealing how marketing & regulation fuel this trend—and what it m...

GLP-1 Crackdown: Makary & the Future of Drug AccessHealth

GLP-1 Crackdown: Makary & the Future of Drug Access

Uncover the hidden forces behind the GLP-1 drug debate! Our analysis reveals how FDA oversight, market demand, & Dr. Makary's actions reshape access.

AI & FDA: Abramson Hire Signals Industry's Rising InfluenceHealth

AI & FDA: Abramson Hire Signals Industry's Rising Influence

Uncover the hidden implications of a key FDA hire! Our analysis reveals how industry influence is reshaping AI regulation, and what it means for patient safety.